AU1555099A - Liquid presentations of oxazaphosphorine-containing pharmaceutical products - Google Patents

Liquid presentations of oxazaphosphorine-containing pharmaceutical products

Info

Publication number
AU1555099A
AU1555099A AU15550/99A AU1555099A AU1555099A AU 1555099 A AU1555099 A AU 1555099A AU 15550/99 A AU15550/99 A AU 15550/99A AU 1555099 A AU1555099 A AU 1555099A AU 1555099 A AU1555099 A AU 1555099A
Authority
AU
Australia
Prior art keywords
oxazaphosphorine
pharmaceutical products
containing pharmaceutical
methanesulfonyloxyethyl
chlorethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15550/99A
Inventor
Matthias Bayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stada Arzneimittel AG
Original Assignee
Stada Arzneimittel AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7845441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU1555099(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stada Arzneimittel AG filed Critical Stada Arzneimittel AG
Publication of AU1555099A publication Critical patent/AU1555099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Abstract

The invention relates to a ready-to-use liquor which is stable in storage and comprises at least one active agent from the group of oxazaphosphorines with general formula (I), in which R1, R2 and R3 are either identical or different, and mean hydrogen, methyl, ethyl, 2-chlorethyl or 2-methanesulfonyloxyethyl, on the condition that R3 does not mean hydrogen, and that at least two of these radicals are 2-chlorethyl and/or 2-methanesulfonyloxyethyl. The solution also comprises a physiologically well-tolerated compound which forms chloride ions in the aqueous liquor, and, optionally, at least one solutizing auxiliary agent and/or at least one buffer substance.
AU15550/99A 1997-10-13 1998-10-13 Liquid presentations of oxazaphosphorine-containing pharmaceutical products Abandoned AU1555099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19745246 1997-10-13
DE19745246 1997-10-13
PCT/DE1998/003052 WO1999018973A2 (en) 1997-10-13 1998-10-13 Liquid presentations of oxazaphosphorine-containing pharmaceutical products

Publications (1)

Publication Number Publication Date
AU1555099A true AU1555099A (en) 1999-05-03

Family

ID=7845441

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15550/99A Abandoned AU1555099A (en) 1997-10-13 1998-10-13 Liquid presentations of oxazaphosphorine-containing pharmaceutical products

Country Status (6)

Country Link
EP (1) EP1023075B1 (en)
AT (1) ATE348621T1 (en)
AU (1) AU1555099A (en)
DE (1) DE59813853D1 (en)
ES (1) ES2277397T3 (en)
WO (1) WO1999018973A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1555099A (en) * 1997-10-13 1999-05-03 Stada Arzneimittel A.G. Liquid presentations of oxazaphosphorine-containing pharmaceutical products
AUPQ849900A0 (en) * 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
US6906047B2 (en) * 2001-12-13 2005-06-14 Gensia Sicor Pharmaceuticals, Inc. Aqueous ifosfamide composition
US7199111B2 (en) 2002-12-02 2007-04-03 Bharat Serums & Vaccines Ltd. Aqueous ifosfamide compositions for parenteral administration and a process for their preparations
DE10346134A1 (en) * 2003-10-01 2005-04-21 Baxter Healthcare Sa Storage-stable, concentrated or supersaturated aqueous preparations containing the cytostatic agent ifosfamide, obtained using mercatoethanesulfonate-sodium as solubilizer
US20090010887A1 (en) * 2004-10-06 2009-01-08 Ben-Sasson Shmuel A Method and composition for enhancing anti-angiogenic therapy
KR20170008252A (en) * 2014-05-09 2017-01-23 아우로메딕스 파마 엘엘씨 Formulations of cyclophosphamide liquid concentrate
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227374A (en) * 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
ES2038623T3 (en) * 1986-07-11 1993-08-01 Asta Medica Aktiengesellschaft PROCEDURE TO PREPARE OXAZAPHOSPHORIN SOLUTIONS WITH IMPROVED STABILITY.
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
AU1555099A (en) * 1997-10-13 1999-05-03 Stada Arzneimittel A.G. Liquid presentations of oxazaphosphorine-containing pharmaceutical products

Also Published As

Publication number Publication date
ATE348621T1 (en) 2007-01-15
DE59813853D1 (en) 2007-02-01
EP1023075B1 (en) 2006-12-20
WO1999018973A2 (en) 1999-04-22
WO1999018973A3 (en) 1999-08-26
ES2277397T3 (en) 2007-07-01
EP1023075A1 (en) 2000-08-02

Similar Documents

Publication Publication Date Title
MY114389A (en) Aqueous risperidone formulations
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
NZ294464A (en) Stable, aqueous formulation having high biological alpha-type interferon activity buffered from 4.5 to 7.1 and comprising chelating agent and a polyoxyethylene sorbitan monooleate, formulation free from human blood-derived products
NO994621D0 (en) Nutritional formulations containing oligosaccharides
BR9809468A (en) Pharmaceutical formulations containing voriconazole
TR200100574T2 (en) Antiviral agents containing nitrogenous heterocyclic carboxamide derivatives
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
NO981944L (en) Lipopolyamines as transfection agents as well as their pharmaceutical use
BR9713338A (en) Benzonaphyridines as bronchial therapeutics.
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
AU3914097A (en) Preservative systems for pharmaceutical compositions containing cyclodextrins
AU1555099A (en) Liquid presentations of oxazaphosphorine-containing pharmaceutical products
CA2270177A1 (en) Transdermal administration of ment
MXPA02012160A (en) Medicinal compositions containing propenone derivatives.
PL346764A1 (en) New oral formulation for 5-ht4
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
MY132911A (en) Clear, injectable solution of an anesthetic compound
AU591132B2 (en) E-isomers of N alpha-(2-cyano-2-alkoximinoacetyl)-amino acid derivatives and peptides
ATE234868T1 (en) STABILIZER FOR MEDICINAL PRODUCTS
NO980058L (en) Ophthalmic preparations
AU3580995A (en) Derivatives of carbohydrates and compositions containing them
WO2002089770A3 (en) Topical lamellar double membrane structure composition containing n-acyl-ethanolamine and/or a quaternary ammonium salt and/or adenosylmethionine
CA2269502A1 (en) Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraetherlipid derivatives, and use thereof
HUP0004362A2 (en) Parenteral formulations comprising carbamazepine or its derivatives
AU8678682A (en) Aminoglycoside derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase